A Clinical Trial of a Hemp-Derived Cannabidiol Product for Anxiety
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This open-label to double-blind study evaluates the impact of cannabidiol (CBD) on anxiety in
adults. Participants will use a custom-formulated sublingual (under-the-tongue) solution of
whole plant, hemp-derived CBD twice daily for six weeks in addition to their normal treatment
regimen. Participants' clinical state will be assessed weekly during the treatment period.
Quality of life, sleep, general health, and cognitive function will also be assessed.